Corrigendum to "Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study" [Lung Cancer 85 (2014) 415–419]. Issue 2 (February 2015) - Auliac, J.B.; Chouaid, C.; Greillier, L.; Monnet, I.; Le Caer, H.; Falchero, L.; Corre, R.; Descourt, R.; Bota, S.; Berard, H.; Schott, R.; Bizieux, A.; et al.